Immix Biopharma enters ATM equity offering agreement with ThinkEquity LLC

Immix Biopharma, Inc.

ATM Sales Agreement with ThinkEquity LLC allows at-the-market sales of common stock, subject to $75M public float limitation.
Commission rate of 3.75% of gross proceeds; company also reimburses legal fees up to $50,000 and quarterly fees.
Sales may occur on Nasdaq Capital Market or other trading markets at prevailing prices; agreement terminable on 10 days' notice.
Prospectus supplement filed July 14, 2023 under effective shelf registration statement (333-269100).

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immix Biopharma, Inc. entered into ATM Sales Agreement with ThinkEquity LLC (effective 2023-07-14).

Action: entry
Agreement: atm program
Counterparty: ThinkEquity LLC
Effective: 2023-07-14

Exact text from the filing

On July 14, 2023, Immix Biopharma, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”)

View on SEC.gov

Browse all material agreements →

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-024626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.